Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment | 1 | Insider Monkey | ||
ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
12.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
03.06. | H.C. Wainwright bekräftigt Kaufempfehlung für Arcus Biosciences-Aktie | 1 | Investing.com Deutsch | ||
02.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.05. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.04. | Forecasting The Future: 5 Analyst Projections For Arcus Biosciences | 2 | Benzinga.com | ||
26.02. | Arcus Biosciences stock rating upgraded to Buy at H.C. Wainwright | 23 | Investing.com | ||
25.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
25.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
19.02. | Arcus Biosciences stock target cut to $18 at H.C. Wainwright | 4 | Investing.com | ||
18.02. | Arcus Biosciences Shares Are Down Today: What's Going On? | 1 | Benzinga.com | ||
18.02. | Arcus Biosciences Prices 13.6 Mln Offering At $11.00/shr, Stock Slide In Pre-market | 1 | RTTNews | ||
18.02. | Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry | 5 | Investing.com | ||
18.02. | Arcus Biosciences stock dips after pricing $150M offering | 1 | Seeking Alpha | ||
18.02. | Arcus Biosciences treibt Krebsmedikament Casdatifan nach Auslaufen des Gilead-Deals voran | 16 | Investing.com Deutsch | ||
18.02. | Arcus Biosciences sets $11/share for $150M stock offering | 1 | Investing.com | ||
18.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
21.01. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 94,10 | -0,26 % | Moderna mit Erfolg in Phase 3: Grippeimpfstoff des BioNTech-Konkurrenten zeigt Wirkung | Moderna hat in einer Phase-3-Studie zur Wirksamkeit des saisonalen Grippeimpfstoff-Kandidaten mRNA-1010 positive Ergebnisse erzielt. In der Studie mit über 40.000 Teilnehmern ab 50 Jahren zeigte mRNA-1010... ► Artikel lesen | |
CUREVAC | 4,576 | -0,04 % | CureVac mit BLITZMELDUNG: Könnte die Aktie am Montag komplett einbrechen - Experten empfehlen SOFORT zu handeln! | ||
STRYKER | 334,80 | +0,27 % | Dividendenbekanntmachungen (30.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1706 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1808 EUR ADVANCED FLOWER CAPITAL... ► Artikel lesen | |
INFLARX | 0,690 | +1,17 % | Evotec, GFT Technologies, InflaRx, Nordex, Rheinmetall, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 9,122 | +0,86 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy ... | With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median... ► Artikel lesen | |
VAXART | 0,381 | +3,75 % | Vaxart wird vom Nasdaq ausgesetzt und plant Berufung gegen Delisting-Entscheidung | ||
NEUROCRINE BIOSCIENCES | 108,45 | 0,00 % | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist | SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study... ► Artikel lesen | |
HALOZYME THERAPEUTICS | 45,730 | +0,31 % | Halozyme Therapeutics in den Russell 1000 Index aufgenommen | ||
XOMA ROYALTY | 22,400 | +2,75 % | Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right | EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq-CM:... ► Artikel lesen | |
IMMATICS | 4,706 | +0,99 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
MANNKIND | 3,075 | +1,22 % | MannKind Corp. Q1 Sales Increase | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) released a profit for first quarter of $13.16 millionThe company's earnings totaled $13.16 million, or $0.04 per share. This compares with $10.63... ► Artikel lesen | |
BEONE MEDICINES LTD ADR | 212,00 | +1,92 % | We care what you wear: BeOne und CollectiveFour launchen eigene Kollektion für Ärztinnen und Ärzte auf der Berliner Fashion Week | Berlin (ots) - Ein längst überfälliges Update für medizinische Arbeitskleidung.Medizinerinnen und Mediziner stehen jeden Tag im Einsatz für unsere Gesellschaft - und doch entspricht ihre Arbeitskleidung... ► Artikel lesen | |
AC IMMUNE | 1,710 | -1,38 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
ESPERION | 1,020 | +2,66 % | Esperion Therapeutics, Inc. - 8-K, Current Report | ||
ROCKET PHARMACEUTICALS | 2,487 | +1,47 % | Rocket Pharmaceuticals stock rises after FDA clearance for heart failure therapy |